October 12, 2006 16:29 ET

bioRASI to Announce Optimized Pipeline Development™ for Generic and 505(b)(2) Drug Candidates

bioRASI to Showcase Success Stories at AAPS Conference in San Antonio, Texas

MIAMI, FL -- (MARKET WIRE) -- October 12, 2006 -- Global CRO bioRASI, a strategic initiative of the 250,000 person-strong Russian Academy of Sciences, announced today that it would unveil the Optimized Pipeline Development™ Program for Generic and 505(b)(2) drug candidates at the 20th Annual Meeting of the American Association for Pharmaceutical Sciences (AAPS).

"We have used Optimized Pipeline Development™ to substantially increase the yield of our clients' innovative drug pipelines for some time. Now we are expanding this powerful approach to Generic and 505(b)(2) drug pipelines," said Dr. Boris Reznik, Chairman of bioRASI. "Optimized Pipeline Development™ leverages our unique global capabilities and access in order to substantially increase the efficiency and effectiveness of the clinical development process, allowing sponsors to move a higher number of candidates through the pipeline."

The AAPS Annual Meeting, taking place in San Antonio, Texas October 28-November 2, is one of the largest gatherings of scientists and executives dedicated to the development of pharmaceutical products. bioRASI will exhibit at booth 889 and will be presenting the application and success stories associated with Optimized Pipeline Development™.

About bioRASI

bioRASI is a full service global CRO uniquely positioned to provide Optimized Pipeline Development™ to biotechnology and pharmaceutical companies. A strategic initiative of the 250,000 person-strong Russian Academy of Sciences, bioRASI conducts research throughout the Americas, Europe, and Asia. bioRASI is experienced in biologicals, medical devices, and small drugs across a wide range of indications, maintaining equal balance between Pilot, Phase I/BE, and Phase II/IV studies. Applying this comprehensive set of capabilities, bioRASI is able to significantly expand and accelerate the development of its clients' therapeutics pipelines. bioRASI is co-headquartered in Miami, FL and Moscow, R.F., and has regional offices across the globe.

Contact Information